Core Viewpoint - The revised Implementation Regulations of the Drug Administration Law of the People's Republic of China have been officially released, emphasizing a legal framework for drug activities that prioritizes public welfare and innovation [1] Industry Summary - The new regulations serve as a tool to refine and implement the Drug Administration Law, indicating a shift towards high-quality development in the pharmaceutical industry, driven by innovation and compliance [1] - The pharmaceutical industry is expected to maintain an overweight position, with investment strategies focusing on three main lines for 2026: 1. Innovation-driven and internationalization, highlighting the importance of companies that focus on innovation and international expansion in a domestic policy environment that discourages excessive competition [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research that can replace imports, especially in light of potential geopolitical risks [1] 3. New policies and new opportunities, benefiting from optimized centralized procurement, three-payment systems in medical insurance, consumption stimulus policies, and state-owned enterprise reforms [1]

Core Viewpoint - The revised Implementation Regulations of the Drug Administration Law of the People's Republic of China have been officially released, emphasizing a legal framework for drug activities that prioritizes public welfare and innovation [1] Industry Summary - The new regulations serve as a tool to refine and implement the Drug Administration Law, indicating a shift towards high-quality development in the pharmaceutical industry, driven by innovation and compliance [1] - The pharmaceutical industry is expected to maintain an overweight position, with investment strategies focusing on three main lines for 2026: 1. Innovation-driven and internationalization, particularly in the context of domestic policies that discourage excessive competition [1] 2. Self-sufficiency, with an emphasis on core components, reagents, and upstream research areas that can replace imports due to geopolitical risks [1] 3. New policies and opportunities, benefiting from optimized centralized procurement, three-payment systems in medical insurance, consumption stimulus policies, and state-owned enterprise reforms [1]

Core Viewpoint - The medical and healthcare industry in China is expected to experience stable and continuous growth driven by innovation and supportive policies, leading to a return to a market pricing system based on clinical value and demand [1] Group 1: Investment Trends - The pharmaceutical industry is projected to maintain an overweight status, with key investment lines focusing on innovation-driven and internationalization strategies, self-sufficiency in core components, and benefits from new policies [1] - The report predicts that 64 out of 76 covered pharmaceutical companies will achieve year-on-year positive growth or remain stable in their performance for Q4 2025/H2, while 12 companies may face negative growth or losses [1] - The acceleration of innovation in pharmaceutical and medical enterprises is expected to translate into performance growth, driven by external business development (BD) and commercialization [1] Group 2: Innovation and Licensing - 2025 is anticipated to be a significant year for the licensing of Chinese innovative drugs, with upfront payments and potential milestones contributing to substantial growth in the financial reports of various pharmaceutical companies [2] - Many biotech firms are expected to realize the global value of their core products through licensing, which will enhance their financial performance and support new rounds of research and development investments [2] - The demand for asset acquisition remains strong among multinational pharmaceutical companies, indicating a sustainable wave of outbound licensing for Chinese innovative drugs [2] Group 3: Industry Chain Insights - The geopolitical influences are diminishing, and the funding structure for domestic pharmaceutical companies is improving, leading to signs of recovery in biopharmaceutical investment and financing [3] - The early-stage research demand for large molecule antibodies and ADCs is recovering, with expectations for increased IPO activity in Hong Kong and a rebound in clinical CRO segments in 2026 [3] - Domestic CDMO companies are expected to stabilize and recover in new order signings, driven by the ongoing demand for new molecules such as ADCs and peptides [3] Group 4: Medical Industry Chain - The medical industry chain is showing signs of recovery, with expectations for continued growth in Q4 2025 and into 2026, particularly in sectors like medical devices, IVD, and OTC traditional Chinese medicine [4][5] - Three main investment lines for 2026 include an improved domestic payment environment for innovative drugs and devices, a harvest period for overseas expansion, and the emergence of new business models such as brain-computer interfaces and AI in healthcare [4][5]

Group 1 - The A-share pharmaceutical sector has shown strong performance this year, with related thematic funds achieving significant returns, but there has been a correction since September, leading to profit-taking and only one fund remaining that has doubled in value [1] - From September to the end of November, the pharmaceutical thematic index has decreased by 9.21%, while it had increased by over 18% from January to the end of August [1] - Among 136 pharmaceutical thematic funds, 10 funds had returns exceeding 100% from the beginning of the year to the end of August, while 39 funds had returns over 50% [1] Group 2 - There are 14 pharmaceutical thematic funds with negative net values this year, with 3 funds experiencing declines exceeding 10% [2] - Industry experts remain optimistic about the investment outlook for the pharmaceutical sector, citing factors such as innovation in Chinese pharmaceutical companies and supportive policies for innovative drugs and medical devices [2] - The pharmaceutical industry is expected to maintain an overweight position, with investment strategies focusing on innovation, internationalization, and domestic policy benefits [2]

Core Viewpoint - The medical health industry in China is expected to experience stable and continuous growth driven by innovation, supportive policies, and a return to a market pricing system based on clinical value and demand, leading to a positive outlook for listed companies [1] Summary by Categories Investment Trends - By 2026, the pharmaceutical investment trend will be influenced by the concentration of innovation in Chinese pharmaceutical companies and a series of supportive policies aimed at promoting innovative drugs and medical devices, optimizing procurement, and enhancing commercial insurance [1] Market Environment - The medical health industry is anticipated to gradually return to a pricing system that reflects clinical value and demand, fostering a stable domestic pharmaceutical market environment and a long-term growth trajectory for the industry [1] Performance Outlook - Listed companies in the pharmaceutical sector are expected to see sustained and stable performance growth, contributing to a certain degree of industry growth certainty [1] Investment Strategies - Recommended investment strategies for 2026 include: 1. Focus on innovation-driven and internationalization efforts, particularly in the context of a "de-involution" domestic policy environment [1] 2. Emphasize self-sufficiency and the acceleration of import substitution processes for core components, reagents, and upstream research due to potential geopolitical risks [1] 3. Identify beneficiaries of policy changes such as optimized procurement, three-payment systems in medical insurance, consumer stimulus policies, and state-owned enterprise reforms [1]

Core Viewpoint - The pharmaceutical industry in China is expected to maintain a stable and continuous growth trend, driven by innovation and supportive policies, leading to a return to a market pricing system based on clinical value and demand [1] Group 1: Investment Trends - By 2026, the medical health industry is anticipated to benefit from a series of supportive policies for innovative drugs and medical devices, optimization of centralized procurement, and promotion of commercial insurance [1] - The industry is expected to experience a stable domestic market environment and a long-term growth trajectory, providing certainty for industry growth [1] Group 2: Investment Recommendations - Focus on innovation-driven and internationalization strategies, particularly in the context of domestic policy changes that discourage internal competition [1] - Emphasize on self-sufficiency, particularly in core components, reagents, and upstream research areas, to mitigate risks from geopolitical disturbances [1] - Identify opportunities related to new policies, including benefits from optimized centralized procurement, three-payment systems in medical insurance, consumer stimulus policies, and state-owned enterprise reforms [1]